Product Pipeline / Overview
Baliopharm focuses on the development of innovative protein therapeutics for immune mediated inflammatory diseases and cancer.
Immune mediated inflammatory diseases:
The incidence of immune-mediated inflammatory diseases in developed countries is about 5-7% including, within others diseases like rheumatoid arthritis, psoriasis, Crohn`s disease and colitis ulcerosa. Moreover, several neuro-inflammatory and neurodegenerative disorders like multiple sclerosis or Parkinson are known to be immune-mediated.
Targeted biological therapies have revolutionized treatment of immune-mediated inflammatory diseases. The discovery that clinically unrelated conditions, such as rheumatoid arthritis, psoriasis and Crohn`s disease, share similar immune dysregulation has led to a shift in the management of immune-mediated inflammatory diseases from one of organ based symptom relief to mechanism-based treatment. Especially monoclonal antibodies have become a well validated and established treatment option for several of these indications. However, there is significant room for improvement regarding the specificity and drug mediated side effects.
ATROSAB, the lead compound of Baliopharm is a new generation humanized antibody specifically binding to the Tumor-necrosis factor receptor 1 and thus is indicated for a variety of immune mediated inflammatory diseases. Phase I study has been finalized in 2014 demonstrating the safety profile of ATROSAB and defining the MTD. The company is currently preparing the phase II trial as well as an improved formulation for subcutaneous application
Due to the specific interaction with the TNF-receptor 1 ATROSAB is one of the first anti-TNF drug developed which could be used for the treatment of multiple sclerosis. Therefore, Baliopharm is currently developing a special formulation, called ATROSAB –MS for this indication.
Baliopharm has in-licensed a platform technology to design bi-specific antibodies which will allow the generation of superior antibody therapeutics by increasing the selectivity for the respective targets with the aim to increase efficacy and safety. The first bi-specific antibody, NOVOTARG, constructs to be developed will target the CD20 and CD95 receptor. This compound will be indicated for the treatment of B-cell malignancies like B-cell lymphoma and chronic lympholytic leukemia as well as for several autoimmune diseases. In the preclinical studies Baliopharm will focus on the treatment of multiple sclerosis.
The bispecific concept is also applicable to a variety of different target antigens, such as CD19, CD40, tenascin and NG2 and is protected by a granted patent.
Overview of Pipeline